Please login to the form below

Not currently logged in
Email:
Password:

radioligand therapy

This page shows the latest radioligand therapy news and features for those working in and with pharma, biotech and healthcare.

Novartis receives EC approval for Pluvicto to treat adult cancer patients

Novartis receives EC approval for Pluvicto to treat adult cancer patients

More than 80% of patients highly express a phenotypic biomarker called PSMA, making it a promising diagnostic and therapeutic target for radioligand therapy, Novartis said. ... The trial met its primary endpoint, with Pluvicto demonstrating a

Latest news

More from news
Approximately 4 fully matching, plus 5 partially matching documents found.

Subscribe to our email news alerts

PMHub

Add my company
Lucid Group Communications Limited

WE’RE ON A MISSION To transform lives through communication that changes behaviour and improves health outcomes....

Latest intelligence

Whitepaper: Closing the gap with compelling healthcare communications
Want to learn how to close the distance between a person’s current health and their healthiest possible self?...
Healing the Healers
Because if we do not heal the healers, who is going to heal us?...
The (inevitable) digital transformation of Medical Affairs
It’s not a question of ‘if,’ it’s a question of ‘when.’...